Compare Stocks → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:CBMNASDAQ:CORTNASDAQ:DRNANASDAQ:EIDXNASDAQ:QURE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMCambrex$59.99$59.99$33.80▼$60.29$2.02B2.14218,726 shsN/ACORTCorcept Therapeutics$25.32+2.3%$23.33$20.87▼$34.28$2.56B0.47907,476 shs746,706 shsDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AQUREuniQure$5.41+1.7%$5.59$4.76▼$22.48$254.50M0.971.38 million shs600,446 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMCambrex0.00%0.00%0.00%0.00%0.00%CORTCorcept Therapeutics+2.30%+3.73%+9.47%-22.99%+15.88%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%QUREuniQure+1.69%+3.44%-15.20%-20.79%-73.04%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBMCambrexN/AN/AN/AN/AN/AN/AN/AN/ACORTCorcept Therapeutics4.5707 of 5 stars3.30.00.04.31.33.33.1DRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AQUREuniQure2.0774 of 5 stars3.41.00.00.03.32.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBMCambrexN/AN/AN/AN/ACORTCorcept Therapeutics2.67Moderate Buy$33.7933.43% UpsideDRNADicerna PharmaceuticalsN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AQUREuniQure2.71Moderate Buy$32.00491.50% UpsideCurrent Analyst RatingsLatest CBM, QURE, CORT, EIDX, and DRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2024QUREuniQureMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $7.003/1/2024QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.002/29/2024QUREuniQureThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$63.00 ➝ $8.002/16/2024CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $42.001/19/2024QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.001/16/2024QUREuniQureRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$28.001/2/2024CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $28.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBMCambrex$532.09M3.80$3.91 per share15.36$19.48 per share3.08CORTCorcept Therapeutics$482.38M5.43$0.98 per share25.84$4.92 per share5.15DRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74QUREuniQure$15.84M16.34N/AN/A$4.34 per share1.25Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBMCambrex$92.41M$2.7721.66∞N/A5.96%5.38%2.50%N/ACORTCorcept Therapeutics$106.14M$0.9526.6519.48N/A21.86%21.98%17.89%5/1/2024 (Estimated)DRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AEIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AQUREuniQure-$308.48M-$6.48N/AN/AN/A-1,947.09%-99.31%-37.65%5/14/2024 (Estimated)Latest CBM, QURE, CORT, EIDX, and DRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023QUREuniQure-$1.54-$1.53+$0.01-$1.53$3.20 million$6.69 million2/15/2024Q4 2023CORTCorcept Therapeutics$0.25$0.28+$0.03$0.28$129.27 million$135.41 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBMCambrexN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBMCambrex0.762.371.70CORTCorcept TherapeuticsN/A4.394.31DRNADicerna PharmaceuticalsN/A2.462.46EIDXEidos Therapeutics0.1411.1011.10QUREuniQure0.498.858.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBMCambrex90.96%CORTCorcept Therapeutics93.61%DRNADicerna Pharmaceuticals78.91%EIDXEidos Therapeutics31.40%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipCBMCambrex1.41%CORTCorcept Therapeutics19.80%DRNADicerna Pharmaceuticals10.20%EIDXEidos Therapeutics70.10%QUREuniQure4.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBMCambrex1,73233.72 millionN/AOptionableCORTCorcept Therapeutics352103.52 million83.02 millionOptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableQUREuniQure48047.84 million45.90 millionOptionableCBM, QURE, CORT, EIDX, and DRNA HeadlinesSourceHeadlineUniQure (QURE) Reports Q4 Loss, Tops Revenue Estimateszacks.com - February 28 at 9:20 AMuniQure Announces 2023 Financial Results and Highlights Recent Company Progressglobenewswire.com - February 28 at 7:05 AMuniQure: The AMT-130 Readoutseekingalpha.com - July 17 at 1:47 PMMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureseekingalpha.com - May 22 at 5:38 PMuniQure: Financials And Pipeline Signal A Promising Outlook For Investorsseekingalpha.com - May 20 at 9:19 AMWhy Sunstar's unique M&A model is attractive to independent agencies - Insurance Businessinsurancebusinessmag.com - February 7 at 2:42 PMUnique new Greenville business hoping to lather up same success of other locations - WNCTwnct.com - February 7 at 2:42 PMNew: The Buffalo Gift Emporium is Expanding its Unique Selection of Gifts - Step Out Buffalostepoutbuffalo.com - February 7 at 2:42 PMMarshall fire victims with no renter's insurance face unique obstacles - The Colorado Suncoloradosun.com - February 7 at 2:42 PM'Chess on ice:' Curling classes give Olympic viewers chance to try unique sport in Grand Rapids - MLive.commlive.com - February 7 at 2:42 PMReview: Bittersweet, quirky 'Sapience' takes unique look at the hurdles of communication - The San Diego Union-Tribunesandiegouniontribune.com - February 7 at 2:42 PMHappy Rose Day: 5 Unique Rose Recipes You Can Make For Loved Ones - NDTV Foodfood.ndtv.com - February 7 at 9:41 AMUnique partnership solves UP bridge problem | News, Sports, Jobs - Escanaba Daily Pressdailypress.net - February 7 at 9:41 AMGeneva's Little Traveler to celebrate 100 years of unique shopping experience - Shaw Localshawlocal.com - February 7 at 9:41 AMPenguins duo unveils unique NIL deal with Austintown business - Warren Tribune Chronicletribtoday.com - February 7 at 9:41 AMDozens of unique vendors set up shop for Craft Fair - Marshalltown Times Republicantimesrepublican.com - February 7 at 9:41 AMUnique math class helps students build their futures - FOX 31 Denverkdvr.com - February 7 at 9:41 AMA DoSeum experience as unique as you and me - San Antonio Reportsanantonioreport.org - February 7 at 9:41 AMuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireglobenewswire.com - February 7 at 9:41 AMuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Diseasefinance.yahoo.com - February 7 at 9:41 AM'Cats on Mats' gives Bloomington adoption event a unique twist - HOI ABChoiabc.com - February 6 at 8:12 AMWould You Ride...These Crazy Unique Roller Coasters? - Theme Park Touristthemeparktourist.com - February 6 at 3:12 AM'Cats on Mats' gives Bloomington adoption event a unique twist - week.comweek.com - February 6 at 3:12 AMHow Steph Curry impacts Jonathan Kuminga, Moses Moody's unique rookie seasons - NBC Sports Bay Areanbcsports.com - February 6 at 3:12 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCambrexNYSE:CBMCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Corcept TherapeuticsNASDAQ:CORTCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Dicerna PharmaceuticalsNASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Eidos TherapeuticsNASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.uniQureNASDAQ:QUREuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.